The results of the ARTEN study demonstrate the noninferiority in efficacy of NVP compared with ATZ/r, when combined with TDF/FTC, with the advantage of a potentially more
IDH inhibitor favourable lipid profile. This study, therefore, supports the consideration of NVP as part of initial ARV regimens in treatment-naïve patients with the recommended CD4 cell count thresholds, in particular for those at increased cardiovascular risk. This study was sponsored by Boehringer Ingelheim GmbH. The authors wish to thank the patients, investigators, clinicians and nursing staff who participated in the trial. Conflicts of interest: Daniel Podzamczer has received research grants and/or honoraria for participation in advisory boards and/or conferences from Boehringer Ingelheim, BMS, Janssen, GSK, Abbott, MSD, Pfizer and ViiV. Bonaventura Clotet has served during the past 2 years as a consultant on advisory boards, participated in speakers’ bureaus and conducted clinical trials with Boehringer Ingelheim, Abbott, GSK, Gilead, Tibotec, Janssen, Merck, Shionogi and ViiV. Stephen Taylor has received research grants and/or honoraria for participation in scientific advisory boards and/or speaking SB203580 engagements at scientific conferences from Boehringer Ingelheim, BMS, Janssen, GSK, Abbott, MSD, Pfizer, Roche and ViiV. Jürgen Rockstroh
has served as a scientific advisor to Abbott, Boehringer Ingelheim, BMS, Gilead, GSK, Merck, Tibotec, ViiV and Bionor. He has served on data and safety monitoring boards for Hofmann La Roche and Pfizer and has received honoraria for speaking engagements at scientific conferences from Abbott, Boehringer Ingelheim, BMS, Gilead, GSK and ViiV. He has
received research support from Abbott, Hofmann La Roche and Merck. Peter Reiss Amoxicillin has served as a scientific advisor to Boehringer Ingelheim, BMS, Gilead, GSK, Merck, Theratechnologies Inc., Tibotec and Tobira Therapeutics. He has served on data and safety monitoring boards and endpoint adjudication committees for Tibotec and has received honoraria for speaking engagements at scientific conferences from Boehringer Ingelheim, BMS, Gilead, GSK and Theratechnologies, Inc. He has received research support from Gilead, ViiV and Boehringer Ingelheim. Pere Domingo has received research grants and/or honoraria for participation in advisory boards and/or conferences from Boehringer Ingelheim, BMS, Janssen, GSK, Abbott, MSD, Pfizer, Theratechnologies, Inc. and ViiV. Vincent Soriano has received grants and/or honoraria for participation in advisory boards and/or conferences from Boehringer Ingelheim, BMS, Janssen, ViiV, MSD, Gilead and Roche. Holger J. Gellermann, Lothar de Rossi and Victoria Cairns are all employees of Boehringer Ingelheim. Manuscript preparation: Boehringer Ingelheim GmbH provided funding for editorial assistance.